Mayinglong Pharmaceutical Group Co., Ltd., together with its subsidiaries, manufactures and sells Chinese and Western medicines in China and internationally. It operates through three segments: Pharmaceutical Manufacturing; Pharmaceutical Wholesale and Retail; and Medical Services. The company offers functional cosmetics, care products and food, Chinese herbal medicines, and medical devices. It also manufactures, processes, and sells pharmaceutical packaging materials, cosmetics, and Chinese medicines; produces and sells health food; and offers class I and II medical devices, machinery, household goods, electronic products, daily necessities, hygiene products, and disinfection products, as well as road freight transportation services. In addition, the company is involved in the retail and wholesale of medical devices and medicines; imports raw and auxiliary materials, machinery and equipment, instruments and meters, spare parts and related technologies; and exports its products. Mayinglong Pharmaceutical Group Co., Ltd. was founded in 1582 and is headquartered in Wuhan, China.
Research context
Mayinglong Pharmaceutical Group Co., LTD appears in PyInvesting’s Shanghai Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- CNY
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
5 years, 6 months ago
Mayinglong Pharmaceutical Group Co., LTD is currently in a long term uptrend where the price is trading 26.0% above its 200 day moving average.
From a valuation standpoint, the stock is 70.9% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 2.8.
Mayinglong Pharmaceutical Group Co., LTD's total revenue rose by 35.0% to $1B since the same quarter in the previous year.
Its net income has increased by 34.2% to $90M since the same quarter in the previous year.
Finally, its free cash flow fell by 118.6% to $-65M since the same quarter in the previous year.
Based on the above factors, Mayinglong Pharmaceutical Group Co., LTD gets an overall score of 4/5.